Main Industry
Health Care
Main Product/Service
1. SNP-6 Series
2. SNP-8 Series
2. SNP-8 Series
Founded Year
2014
Unified Business No.
54727599
Status
Active
Number of Employees
0
Total Paid-in
Capital
713,016,900 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2017)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
SINEW PHARMA INC. (stock code: 6634.TWO), founded in June 2014, is a publicly-listed biotech company dedicated on the development of therapeutic products for solving urgent and important unmet medical needs.
Leveraging its expertise in three core technologies of "In vitro Co-culture Hepatic Cellular Models," "Hepatic Metabolic Enzyme Activity Regulation Models" and "Pharmacokinetic-driven New Drug Development System”, SINEW is focused on two main disease areas:
Metabolic dysfunction–associated steatohepatitis (MASH) and its associated conditions, such as liver cirrhosis and liver cancer.
Acetaminophen-induced hepatotoxicity and severe liver injury.
Driven by the demands in these disease areas, SINEW aspires to become a leading pharmaceutical company by actively engaging in R&D for MASH drug development as well as for the world's first new acetaminophen with high liver safety.
Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations, and one serves as an antidote for acetaminophen overdose.
Leveraging its expertise in three core technologies of "In vitro Co-culture Hepatic Cellular Models," "Hepatic Metabolic Enzyme Activity Regulation Models" and "Pharmacokinetic-driven New Drug Development System”, SINEW is focused on two main disease areas:
Metabolic dysfunction–associated steatohepatitis (MASH) and its associated conditions, such as liver cirrhosis and liver cancer.
Acetaminophen-induced hepatotoxicity and severe liver injury.
Driven by the demands in these disease areas, SINEW aspires to become a leading pharmaceutical company by actively engaging in R&D for MASH drug development as well as for the world's first new acetaminophen with high liver safety.
Current pipeline includes six products, two of which are dedicated to MASH treatment, three aim to address liver toxicity issues arising from the widely used painkiller acetaminophen and its combinations, and one serves as an antidote for acetaminophen overdose.
